📊 poll results
Moderna's cancer vaccine stock rocketed 177% then crashed 25% the next day — and RFK Jr had axed $500M in mRNA funding a year earlier. Who read this right?
🏆 Leading: This was speculation running ahead of the facts. Merck and Moderna hadn't even released the actual numbers — "clinically meaningful improvement" is marketing language, not data. A single day move that nearly triples a company's value, followed by a 25% reversal, looks like hype correcting itself, not a rational re-pricing of a breakthrough.

This was speculation running ahead of the facts. Merck and Moderna hadn't even released the actual numbers — "clinically meaningful improvement" is marketing language, not data. A single day move that nearly triples a company's value, followed by a 25% reversal, looks like hype correcting itself, not a rational re-pricing of a breakthrough. is leading so far with 50%.

The real story is political irony. A year after HHS Secretary RFK Jr. axed roughly $500 million from mRNA vaccine research over doubts about the technology, that same mRNA platform just produced one of oncology's biggest wins in years — proof mRNA's future was never just about COVID shots, and that the funding cuts were shortsighted. is second. On this few votes the split is still anyone's guess.

Everyone who has answered so far is voting from China.

The poll is still live and picked up a vote today.

hewsay who say wut? 💬
📊 poll results
Moderna's cancer vaccine stock rocketed 177% then crashed 25% the next day — and RFK Jr had axed $500M in mRNA funding a year earlier. Who read this right?
50%
Leading answer
This was speculation running ahead of the facts. Merck and Moderna hadn't even released the actual numbers — "clinically meaningful improvement" is marketing language, not data. A single day move that nearly triples a company's value, followed by a 25% reversal, looks like hype correcting itself, not a rational re-pricing of a breakthrough.
results so far
hewsay.com ↗

Discussion

Vote on one of these nextModerna Stock Exploded 177% in One Day on a Cancer Vaccine Breakthrough -- Is This Justified Science, Pure Hype, or a Short-Squeeze Overreaction?Moderna Stock Nearly Triples in a Day -- Cancer Breakthrough, Flu Shot Win, or Just a Short Squeeze?48% of Americans hope AI cures cancer or Alzheimer's — but only 15% trust the companies building it. Is that optimism justified?
react to this tea 👀
The market got it right. This is a genuine landmark — the first-ever Phase 3 proof that a personalized mRNA cancer vaccine actually works. The 177% pop reflected real science; the next-day dip was just normal profit-taking after an outsized rally, not doubt about the result.
This was speculation running ahead of the facts. Merck and Moderna hadn't even released the actual numbers — "clinically meaningful improvement" is marketing language, not data. A single day move that nearly triples a company's value, followed by a 25% reversal, looks like hype correcting itself, not a rational re-pricing of a breakthrough.
The real story is political irony. A year after HHS Secretary RFK Jr. axed roughly $500 million from mRNA vaccine research over doubts about the technology, that same mRNA platform just produced one of oncology's biggest wins in years — proof mRNA's future was never just about COVID shots, and that the funding cuts were shortsighted.